Semaglutide
GLP-1 Receptor Agonist- Drug Class
- GLP-1 Receptor Agonist
- Mechanism of Action (MOA)
- Activates GLP-1 receptors → glucose-dependent insulin secretion, ↓ glucagon, delayed gastric emptying, ↑ satiety.
- Black Box Warning
- Thyroid C-cell tumors in rodents — contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2.
- Clinical Notes
- T2DM and chronic weight management; cardiovascular benefit. Nausea, weight loss, and pancreatitis risk.
- Source
- FDA label
Sources
Reviewed September 2026- FDA label — FDA / DailyMed
Checked against the guideline or standard reference the exam keys to. If it has moved, use Report an error below.
Used for
Same family
Got a pharmacology lecture that covers Semaglutide? Turn it into flashcards and board-style questions, free. Drop it on the home page
All pharmacology